Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Domain Therapeutics Wins EUR 933,000 Grant for Schizophrenia Project

Published: Wednesday, March 14, 2012
Last Updated: Tuesday, March 13, 2012
Bookmark and Share
GPCR specialist will lead EUR 5.1 million ATHOS Project to develop new therapies.

Domain Therapeutics has announced that the ATHOS project has been selected for French government funding. ATHOS aims to develop new drug candidates and identify therapeutic targets for schizophrenia.

Total funding will amount to EUR 5.1 million over three years. Some 45 per cent of the ATHOS budget will be provided by central and regional government organizations, including the grant of EUR 933,000 to Domain Therapeutics.

Schizophrenia is a disease of the central nervous system generally starting in adolescence and becoming a chronic condition. It typically exhibits a dissociation of the personality, giving rise to auditory hallucinations, paranoid delirium and attention disorders.

These problems affect not only the patient’s mental health but also life expectancy, which is 12 years shorter than that of the general population.

Schizophrenia and related conditions affect two to three per cent of the world population but existing treatments do not improve the cognitive disturbances resulting from the disease and some patients remain completely resistant to available treatments.

The ATHOS project will focus on a single class of therapeutic targets, orphan GPCRs. GPCRs are the target for 40 per cent of drugs currently on the market and hence represent the largest class of therapeutic targets.

Orphan GPCRs however have been less explored due to the lack of an identified endogenous ligand. This means these orphan GPCRs, of which some 150 have been described to date, offer a huge therapeutic potential.

Led by Domain Therapeutics, the ATHOS consortium includes Prestwick Chemical, a medicinal chemistry specialist, and the Brigitte Kieffer laboratory at the Institute of Genetics and Molecular and Cellular Biology, which also specializes in GPCRs.

The Brigitte Kieffer laboratory will be in charge of mapping orphan GPCRs in the brain and obtaining appropriate animal models to validate targets for neuropsychiatric disorders.

Prestwick Chemical will apply its expertise in optimizing active compounds.

“Domain Therapeutics know-how in the field of GPCRs combined with our proprietary technology, DTect-All™, and the excellence of our two partners will enable us to bring a solution to this challenge of identifying candidate drugs targeting orphan GPCRs linked to schizophrenia,” said Pascal Neuville, CEO of Domain Therapeutics.

Neuville continued, “The ATHOS project allows us to extend our franchise in neuropsychiatric disorders and in challenging and innovative therapeutic targets.”

The substantial funding being made available comes from a French government fund (Fonds Unique Interministériel), the Alsace Region and OSEO, an agency active in funding innovative projects.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Domain Therapeutics Appoints Professor Michel Bouvier
The world-renowned GPCR specialist will assemble a team of experts in drug discovery and development to guide Domain’s programs.
Tuesday, September 23, 2014
Domain Therapeutics Enters into Collaboration with XOMA
DTect-All™ platform will be used to screen for GPCR-directed allosteric modulator antibodies.
Wednesday, February 05, 2014
Domain Therapeutics Opens a North American Subsidiary at Montreal's NEOMED Institute
Canada-based Domain Therapeutics NA Inc. will focus exclusively on leveraging the BioSens-All™ technology.
Tuesday, January 21, 2014
Domain Therapeutics, Universite de Montreal, IRICoR and McGill University Sign Agreement
New licensing and partnership agreement on G-Protein Coupled Receptor biosensor technology.
Thursday, December 26, 2013
Domain Therapeutics and Ono Sign Collaboration Agreement
Collaboration agreement in the field of GPCR-based drug discovery.
Tuesday, October 23, 2012
Domain Therapeutics Closes EUR Two Million Funding Round
The funds will enable the company to strengthen its position as a strategic collaborative partner to the pharmaceutical industry for discovering drugs targeting GPCRs.
Wednesday, July 18, 2012
Domain Therapeutics Awarded Grant from The Michael J. Fox Foundation
The grant is for the optimization and pharmacological characterization of novel metabotropic glutamate receptor III Positive Allosteric Modulators to treat Parkinson's disease.
Tuesday, January 31, 2012
Domain Therapeutics and Merck Serono Announce an Agreement to Develop Drugs for Parkinson’s Disease
Domain Therapeutics and Merck Serono Announce an Agreement to Develop Drugs for Parkinson’s Disease.
Monday, January 17, 2011
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos